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Polymorphonuclear leukocytes contain well-defined 
proteolytic enzymes in their azurophilic granules 
that can be released into tissues during inflammation. 
producing a localized excess of proteases that causes 
a protease-antiprotease imbalance with subsequent 
tissue destruction. The antiproteolytic compounds of 
the epidermis. such as the protease inhibitors elafin 
and antileukoprotease. are thought to counteract the 
proteolytic tissue damage. We investigated the urine 
of patients suffering from inflatnmatory skin condi-
tions (e.g .• erysipelas. psoriasis) for the presence of 
urinary antiprotease activities. Purification of elas-
tase-inhibitory activities from pooled urine samples 
by cation exchange high-performance liquid chro-
matography and preparative and analytical reverse-
phase high-performance liquid chromatography 
yielded two different types of inhibitors. One was a 
H um an leukocyte e lastase (HLE) is a major serine protease of the azurophilic granules of p olymor-phonuclear le ukocytes and may cause tissue dam-age o nce it is released in areas of inflammatio n [1] . HLE is capable o f causing broad-range tissue de-
structio n by hydrolyzing important insoluble m acrom o lecules such 
as e lastin [2), ke ratin, * and collagen types III [3) and IV [4) . In 
addition , soluble proteins li ke complem ent facto r C5 l5] and 
coagulatio n factors such as an ti thromb in Ill [6] arc hydrolyzed by 
HLE. At first, interest focused on the in volvem e nt of HLE in the 
pathophysiology of lung emphysema l7) , but late ly HLE ha s been 
thought to participate in other di seases includin g parodontosis [8] 
and psorias is [9] as well as adult respiratory distress syndro m e [1 0], 
cystic ftbrosis fll ] , and septicemja [12]. 
In the area of inflammation, neutro phils arc able to form a 
microenviro nm ent w ith insoluble substrates. The release ofproteo-
lytic enzymes in close contact with physiologic substrates results in 
a loc<l l protcase-antiprotease imbalance w ith excess enzymatic 
activ ity [1 3J. HLE re leased from leukocytes is counte racted by a,-
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cationic. acid-stable. and elastase-specific inhibitor 
of M. 6.000 by size-exclusion high-performance liq-
uid chromatography. N-terminal amino acid se-
quence analysis of the first 28 residues showed iden-
tity with elafin. an elastase-specific inhibitor recently 
isolated from psoriatic scales . The second anti-
protease activity was due to two forms of urinary 
bikunin. the inhibitory subunit of inter-a-inhibitor. 
Both bikunin fragments. with M. 4.000 and 16.000. 
were identified by N-terminal amino acid sequence 
analysis of the first 10 residues and were character-
ized by an antiproteolytic profile against human leu-
kocyte elastase. cathepsin G. and trypsin. Urinary 
protease inhibitors may serve as diagnostic markers 
of inflammatory diseases. Key lllOrds: elafinlelastasel 
psoriasisliujlammation. J Invest Dermatol 105:5 62-5 66, 
1995 
pro te inase inhibitor, an M,. 54 ,000 serin e protease inhibito r present 
in high con centration in plasma but also in interstitial fluid [1) . ln 
addition to a 1-prote inase inhibito r, a low-molecular-we ight serine 
protease inhibito r derived from human mucous secretions, antileu-
koprotease/secretory leukocyte protease inl-llbi tor (1 4), was shown 
to inte rfe re with the proteolytic action of substrate-bound HLE at 
the loca l n eutrophjl-subs tra te in terface [1 5). 
R ecently a low-molecula r- weight inhibitor, elafin, h as been 
isolated fi:om human p soriatic scales (1 6). Elafi n , an M r 5999 poly-
peptide, demonstrates specifi c inhibitory activity against elastin-
degrading se rine proteases like HLE, pro te inase 3, and porcine 
pancreatic e lastase (17). 
A furth er source of low-molecular-weight inl-llbitors for H LE 
and cathep sin G in serum and urine is inte r-a -trypsin-inl-llbitor, a 
220-k.D serine protease inhibito r consisting of a complex of three 
subunits. T he antiproteolytic activity is located in the bikunin 
subuni t, form erly named urinary trypsin inhibitor. Neutropl-lll-
derived e lastase and cathepsin G are capable of degrading inter- a -
trypsin-inhjbitor into smaller fragments, among w hich bikunin is 
excreted in urine [1 8,19). 
Previous results showed 1-llgh antiproteolytic activity in urine of 
patients with inflammatory skin disorde rs:r The present study was 
undertaken to e lucidate furth e r the role and the metabolism of 
low-molecular-weight inhibitors such as antileukoprotease (20) 
and elafin [1 6] previously identified in human skjn _ 
O ur prev io us data showed th e presence of HLE inhibitors in 
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urine samples of patie nts with inflammatory skin disorders . Elastase 
inhibitory ac tivity (E lA) was shown to be d e rived fi·om three 
sources, e lafin and two ac tive fi·agm e n ts o f urinary bikunin. 
MATERIALS AND M ETH O DS 
Chemicals Methoxy- succitt yl-alanyl-alanyl-pro l)•l-valine-p-nitroanilide 
(M e O-Suc-A !a-Ala-Pro-Vai-N A). succin yl-alanyl- alanyl-prolyl-phcnylala-
nin e -p-nitroanilide (Suc-Ala-Ala-Pro-l'he-NA) . tosyl-glycyl-prolyl-lysine-
p-nitroanilide (Tos- Giy-Pro-Lys-N A), human plasmin . bo vine pancreatic 
a - c hymo trypsin type 11, porcine pancreati c elastase. and bo vine trypsin 
grade III were obtained from Sigma (St. Lo ui s, M O ) . 1-ILE and human 
cathe psin G were purchased fro m Elastin Products Corporation (Pacifi c, 
MO). Recombinant elafin (e xpressed in yeast) was kindl y provided b y Dr. 
Fi tton (IC I Plnnnaceuti cals. Department o f Bioscience I. Maccles fi eld. 
England) . 
Enzymatic Assays Activi ty of elastase (1-ILE) was measured according to 
the method o f N akajima r 1 nl [21] using MeO-Suc- Aia- Ala-Pro-Val-NA 
(AAPV) as substrate. Ten microliters of each high-performance liquid 
chromatograph y (1-IPLC) fi·actio n we re lyophili zed before addi tion o f n-
(h ydroxyeth yl) pipe ra zine-N-(2-ethane sulfonic acid) assay buffer. 20 ng 
!-ll..E and 0.5 mM AAPV substrate. Elastase activity was determined after 
1 h b y spectropho to metry at 405 nm. Inhibitory activi ty was calcu lated in 
,, re la tio n to the activity of inhjbitor-free controls. Quantificatio n o f EIA was 
perfo rmed by titration w ith active-site titrated I-I LE. Evaluation o f the 
in h ibitory activiti es of chymotryp tic enzymes (cathepsin G . o:-chymon·yp-
sin ) were performed in analogy to the assay given above using 0.5 mM 
Suc-Ala-Ala-Pro-Phe-NA (AAPP) as substrate. Inhibition of trypsin-like 
enzytn es suc h as bov in e trypsin grade UI and hun1an plasn1in \ve rc tn casurcd 
us ing the substrate 0. 1 mM T os- Gly-Pro-Lys-NA . 
Sample Collection and Preparation Urine oftive patients (etysipclas, 
' psori asis vulgari s) was co llected o ver a period of 24 h , pooled and con-
centrated via ul trafi ltra tion with an An1icon YM-1 tn ctnbranc (Atnicon. 
Witten, Germany) . Concen trated urine samples were stirred with perchlo-
ric acid [final concentratio n 5% (v/v)] fo r 30 min at ooc fo llowed by 
neutraliza tion to pi-I 7.5 with KOI-1 . At each step inso lu ble ma terial was 
rem oved by centrifugation at 6000 X g. The supernatants we re concentrated 
' by ultraftltratio n with an Am icon YM-'1 membrane and the resul ting sample 
su bsequentl y subjec ted to HPLC. 
Purification All 1-1 PLC separa tions (Fig 1) were performed with a 
Spectra Physics liquid chromatograph y system equiped wi th an SP 8700 
solvent delivery system , a Kratos spectro flow 783 spectrophoto men·ic 
detector (Kra tos, W estwood , NJ) , and an SP 4270 integrato r. If not stated 
otherwise , ulcravio l<.!t absorption was recorded at 215 nm . 
C ation exchange TSK C M-3 SW HPLC (7.5 X 150 mm , LKB , Bromma, 
Swed en) w as perfo rmed using a linea r gradicm frmn bufFer A (0 .01 M 
amm o nium formate , pH 4.0) to buffer B (0 .5 M ammonium fo rmate, pl-1 
4.0) and final elu tio n with buffer C (0. 5 M ammonium formate, pl-1 3.0). 
Pro te in content was recorded at 280 nm . Fractions demonstrating high 
inhibitory activity against 1-ILE we re selected for further separation and 
ultra filtrated I' in Am icon YM-1 membrane against 0. 1% crifluoroacetic acid 
(TFA). 
The nex t step in line was a preparative reverse-ph:tSe c.-HPLC (Nucleo-
sil 300-7 Cij, 250 mm X 1/z inch , Macherey-Nagcl. Diircn , German y) using 
a linear gradient fro m O.I 'Y.• TFA (buff'er A) to 0. 1% TFA/ acetonitrile (buffer 
B) w ith a fl o w of 3 mil min. 
Relevant fra cti ons from R.P-C. 1-IPLC were fil tered aga inst 0 ."1% T FA. 
Aliquots were applied onto a size- exclusion TSK 2000 SW column (600 X 
7.5 mm , LKB) equiped with a TSK SWP pre-column (75 X 7.5 nnn, LKB) 
fo r the determination of the relative molecular mass. The M, of the 
elastase-inhibiting activity was calcu lated from the retention time after the 
colu.mn had been cali brated w ith various peptides of standardized M, as has 
been reported earlier (16) . Using 0.1 % TFA as eluent this HPLC was 
perfo rmed with a flow of 1 ml / min . 
Further separation was achieved on a po ly- 2-sulfoethyl-aspartamide 
column (Po ly-LC , 200 X 4. 6 mm, C olumbia, MD), which combines the 
fea rures of a cation-exchange and reverse-phase 1-IPLC. The 1-IPLC was run 
at a fl ow o f1 ml / min with 10 ml buffer A (5 mM K.l-1 2 PO .,. pi-1 3. 0, plus 25% 
acetonitrile) fo llo wed by a linea r 30-ml gradient to 50'l'o buffer B (5 mM 
KH2 P04 • pi-1 3.0 . 0.5 M KC I plus 25% acetonitrile) and finall y by 20 ml 
100% buffer B . 
inhibi tor-positive fractions from Poly LC 1-1 l'LC were furth er purified on 
a reverse-phase C 1" column (Nucleosil 100-5 C ,,, 25 0 nun X 4. 6 mm , 
Bischoff, Leon berg, Germany) using a linear gradi ent from 0.1 % TFA to 
0.1% TFA in ace to nitril e. 
Fraction s w ith c l a s t;~ se-inhibitin g activi ty w e re rcchro matographcd on 
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Figure 1. Purification steps on HPLC. Employin g preparati ve I-IPLC 
two different fo rms of E tA, EIA 1 (urinary elafin) and EIA 2 (urinary 
bikunin) were purified to homogeneity. Starting with concemra tcd urine on 
cation-ex hangc TSK-C M HPLC fo llowed by reverse-phase C, 1-fPLC 
urinary e lafin was purified with a combinatio n o f Poly-LC HPLC. reverse-
phase C," and C 4 I-IPLC, whereas the two forms of urinary bikun.in required 
size-exclusion T SK-2000 HPLC and reverse-phase C 4 I-IPLC step for 
purification . 
Po ly LC 1-IPLC before fin al purifica tio n was achieved on an analytical 
reverse-phase C.1 co lumn (Nucleosil l00-C 4 , 250 mm X 4.6 mm , Daker. 
Phillipsburg, NY) runnjng a linea r gradient !Tom 0. 1% T FA co 0.1 % T FA in 
acetonitrile. 
Sodium Dodecylsulfate- Polyacrylamide Gel Electrophoresis (SDS-
PAGE) SDS-PAGE for urina ry bikunins was performed as described by 
Schiigger and Jagow [22J by using a di scontinous system optimized for 
detection of J-20 kD po lypeptides. 
N-Terminal Alnino Acid Sequencing T he peaks from the three final 
analyti ca l reverse-phase C., I-IPLC were subjected to N-terminal amino acid 
sequence analysis by a 476A liquid-phase sequencer (Applied Biosystems, 
Foster C ity. C A) equipped with a re verse-phase PTH C ," column. Cys-
tc incs and scrincs w e re not dc te rntin cd as smnplcs w e re no t dc ri va tized . 
An y position with u11.identifi ed residue was m arked as X position . 
RESULTS 
In pre liminary expe rime nts w e observed hig h ;mtiprotease acti v ity 
in n ati ve urine o f pa ti e nts with inflammatory skin conditions su c h as 
erysipe las or psoriasis vulg at;s . t Subseque ntly, atte mpts w e re m ad e 
to purify the inhibitory ac ti v ity from a pool o f urine from three 
patie nts with psoriasis and two patie nts with e1ys ipe las. 
To re move non acid-stable protease inhibito rs (e .g ., a 1-prote in-
ase inhibitor) fi·om the pudJication process, the pooled urine w as 
fir st treate d with perchloric ac id. T h e concentrated urine sample 
was then applied to catio n-exchan ge HPL C , and three pools of 
fra c tions d e monstrating .EIA were found . A s w e w e re inte res te d in 
ide ntifYing specifi c E IAs we combined fra c tions with hig h anti-
e lastase but low anti-cath e psin G ac tivi ty (Fig 2 , pool II) fo r furth e r 
purification . Pools I and Ill (Fig 2) showed an e ve n distributio n o f 
e lastase and ca thepsin G inhibitory ac tivi ty , bu t inhibitory ac ti v ity 
of p o ol I w as lo st in subsequent purificatio.n ste ps. In pool Ill ove rall 
antiproteoly ti c ac ti v ity was low and the re was n o t e n o ug h m ate i-ial 
to purify the antiproteo ly ti c ac tivity o f poo l III comple te ly . 
The second purification ste p consisted o f a re ve rse- phase C~ 
HPLC . whic h se parated fra c tions conta ining mainly e lastase inhib-
564 STREIT ET AL 
Abs 280 nm 
2 
............. ...... .... .......... ........ 0.5 :s:: 
....... - 0.4 §" 
iii -::I 1.5 
.. ···· 
... .. .. ........... 
... · 
os1 :ul 111 
I I 
I 
I I 
o ;-/---,----.----,---,--~i ~~----------r----r----
% HLE Inhibition 
1 ~~ j Jlll~lllllllllnmlllllllllln11 ... 
% Cathepsin G Inhibition 
100 
50 
0 
min 
0 10 20 30 40 50 60 70 80 90 
Retention time 
~ 0 .1 3 
OJ 
iii 0 
Figure 2. Cation-exchange HPLC of urine samples. Pooled, acidified 
and concentrated urine from fi ve patients with psorin sis (n = 3) or erysipelas 
(n = 2) was applied to a TSK-CM cation-exchange HPLC column . Peptides 
e luted \-Vith n gradi ent of increasing concentration of an11110niun1 fon11atc, 
ultraviolet absorptiun (abs) was recorded at 280 nm. Fractions were tested 
for HLE and ca thepsin G inhibi tory activity . Aliquots with high elastase and 
low cathepsin G inhibitory activity were pooled and used for further puri-
fi ca tion (pool II). 
itory activity (ErA l) fi·om fractions with a combination of elastase/ 
cathepsin G inhibitory activity (E IA 2). 
Employing pre parative HPLC, we purified the EIA 1 to homo-
geneity. Following the reverse-phase C 8 HPLC the combination of 
Poly-LC HPLC with subsequent reverse-phase C, 8 and C 4 HPLC 
resulted in the purification of an e lastase- specific inhibitory activity 
(Fig 3). The calcul ated amount o f EIA showed recovery of only l'V., 
of the EIA ava ilable at the begi nning of the purification process 
(Table 1) . 
Urinary ElA 1 showed an apparent molecu lar mass of 6 kD on a 
ca librated ana lytical TSK-2000 size-exclusion HPLC, the same as 
for recombinant elafin . The specificity of this urinary inh.ibitor for 
serine elastases wa s confirmed by establishing an inhibitor profil e . 
W e observed inhibitory activity only for HLE <llld PPE, but neithe r 
chymotryptic enzymes such as a - chymot1-ypsin and cathe psin G nor 
trypsin and plasmin were affected by a fi vefold m o lar excess ofEIA 
1. 
N-te rminal amino acid sequence analysis (Table II) of the first 
28 residues of the urinary peptide demonstrates identity to psoriatic 
scale-derived clafin [1 6]. Urinary elafin starts with glycine at 
position 7 of the active elafi n pe ptide, wh.ich consists of 57 res idues, 
indicating that it has been cleaved at th e lysine-glycine position. 
T he second inhibitory peak fi·om reverse-pha se C, HPLC dem-
onstrating elastase plus cathepsin G inhibitory activity (EIA 2) was 
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Figure 3. Final purification of clafin from urine. Pooled aliquots from 
a second Poly-LC 1-ll'LC containing ELA 1 were applied on an analytical 
reverse-phase C .1 colwnn resulting in t\VO peaks with antiprorease activity 
(ultraviolet absorbance at 215 nm). The major peak fi·action was selected for 
N-te rn1inal amino acid sequence anal ys is. A rrow 1narks retention ti_me o f 
recombinant (57 aa) elafin. 
purified via analytical TSK-2000 size- exclusion HPLC and reverse-
phase C 4 HPLC. W e obtained two peptides of Mr 4,000 and 16,000 
as shown by SDS-PAGE (Fig 4). Both inhibitory components were 
active against trypsin, elastase, and cathepsin G. The N-terminal 
amino acid sequence analysi s demonstrated identity to urinary 
bikunin , form erly named urinary trypsin in.hibitor , which represems 
an inter- a - trypsin inh.ibitor subunit. 
Step 
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Table I. Recovery of EIA 1 and 2 During the 
Purification Process" 
nn10l EIA (%) 
HPLC EIA I EIA 2 
TSK-CM 8.6 (I 00%) 
RP C" 6.5 (75%) 2. 1 (25%) 
TSK-2000 1.8 (21 %) 
Poly LC 2.3 (27"/.·) 
lt.P C 1H 0.7 (8%) 
Poly LC 0.2 (2%) 
RPC,1 0.08 (1 'X1) 1.6 (18%) 
"Qu;m tif1catio n of EIA wns pc rf'Ormcd with titrntion with active-site titrated HLE. 
Total amount of EIA before start o f purificntion on HPLC was 45 mnol. Pooled 
fra ctio ns o f catio n-exchange TSK-CM HPLC (pool II) yielded 8.6 muol and were 
taken as I OO(Y:1 . Following reverse-phase Ct:l HPLC the EIA was separated in an 
elastase-specific inhibitory component (E.! A I . urinary clafm) :md an elasmsc/cathcpsin 
G inhibi tOry component (EIA 2, 4-kD and 16-kD fragmcnl o f urinary bikunin) . Elafin 
was further puritl cd by poly-2- suiiOcthyl-aspartamidc 1-!PLC. nn<~lyti c :ll reverse-phase 
C 1H and C.1 HPLC. Urin<1ry bikun.in frn gmcnts were isolnted by size- exclusion 
TSK-2000 HPLC and C .1 HPLC. Recovery is given in percent of I"O ta l amounr of 
anti proteolytic acrivi ty at the smrt of the purification process. 
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Table II. Atnino-Acid Sequences of Urinary Antiproteases" 
10 20 30 <10 50 
123456789012345678901234567890 "1234567890 1234567 890 1234567 
I. elafi.ns 
a. GPVXTKPGXXPIILIIUAMLNPPNXXLK ... . . 
b. AQEPVl<G PVSTKPGSCPII L1 R.CA M LNPPN R.C LKDTDCPGI KKCCEGSCG MACFVPQ 
II. urinary bikunins 
a. AVLPQEXXG R. 
b. AVLPQ EEEGSGGGQLVTEVTKKEDSCQLGYS . 
" N-tcrminal amin o-acid sequence of Ia) urinary claftn . this work . compared with !h) 6-kD dafin derived from psoriatic 
sc:tlcs [ 16]. II 11) bo th the .f-kD and J(,-kD fo rm of u rinary hi ku nin. th is work. com pared with lib) urinary bikun in, fOrm erl y 
termed H I 30 , isolat ed 11ia inunohilizcd trypsin (43_[. 
We h ave also demonstrated peaks of inhibitory activit)' co-
eluting with elaf:i n as well as bikunin in samples of patients suffe rin g 
from psoriasis or e rys ipelas (data not shown) . 
D ISCUSSION 
T h e antiproteolytic capacity of human skin has recently becom e a 
field of research interest [1 6,23 ]. Pathogen e tic concepts in volving a 
, local protease / m1tiprotease imbalance have been proposed in sev-
eral inflammato ry diseases [24]. Polym orphonuclear ne utrophils 
conta ining proteolytic enzymes such as e lastase , ca thepsin G, and 
proteinase 3 are conside red to contribute to protease-mediated 
tissu e damage [25]. While screening urine of derma to logic patients 
• for a ntiprotease activi ty, we found high ElA in patients with 
erysipelas and psoriasis:!· The urina ry E IA is comprised of three 
so urces, an active fragm ent of e laf:i n (EIA l) and two fra gm ents o f 
urina ry bikunin (E IA 2) . 
E laf:i n , also named skin-derived anti leukoproteinase, a ca tionic, 
acid- and heat-stable , highly specific inhibitor of human leukocyte 
elastase, porcine pancrea tic e lastase [1 6], and proteinase 3 [17] , 
belongs to the group of low-m olecular-weight serine protease 
inhibitors and was first isolated from psoriatic sca les [1 6]. Elafm was 
found by immunohistochemistry iu the upper layers of the supra-
1 2 3 
Mr 
[kD] 
2.5 
3.5 
8.0 
10.0 
14.5 
17.0 
Figure 4 . High-resolution SDS-PAGE analysis of urina ry bikunin 
, fragments. Urinary bikunin ti·agments (EIA 2) derived from analytical 
reverse-phase C., HPLC demonstrating inhibi tory acti vity aga inst trypsin , 
elastase, and cathepsin G were analyzed in an SDS-PAGE system optimal tor 
sm a iJ peptidcs f22 ] . Lnuc I contains the urinary bikunin ii·agment with an M, 
of 4 kDa. Ln11c 2 shows th e urinary b ikunin fragment w ith an M .. of 16 kD:1 . 
Lnue 3 was loaded with UrCN-cleavage fi·agm cnts of myoglobin (standards). 
basal compartm ent and stratum corneum of lesionaJ psoriatic 
epidermis, but n o t in normal epide rmis [26]. This antiprotease is 
also produced b y w ell-di fferentiated epidermal tumors such as 
squamous cell carcinom a [27]. The gen e product preproelaf:i n was 
found to consist of 117 amino acids, w hich upon cleavage of the 
first 25 amino ac ids results in the form ation of proelafin con taining 
a pro-sequ ence acting as transglutaminase cross-linking m otif and 
the C -te rminal inhibitory active domain of e laf:in /skin-derived 
antileukoproteinase [28]. C ul tured epiderm al keratinocytes express 
12.3 kD preproelafin , w hich upon cleavage of a hydrophobic sign al 
sequence resu lts in proelafin of9.9 kD [29]. T he m ajor free fo rm of 
e laf:i n , as iso lated from psoriatic scales, is a 6-kD peptide [1 6] 
consisting of the 57 C-terminal amino acids of the orig inal 117 
amino acids of preproelafm [28] . U r.inary e lnfi n starts at position 7 
(glycine) of the C -termin al 57 e lafin residu es, indicatin g tha t it has 
been cleaved after the sixth position (lysine). Because of this, the 
urinary peptide found in tlli s study lacks one N-termina l amino acid 
compared with the sm allest scale-de1;ved e lafin fragmen t, which 
starts with lysine at position 6.:j: 
Besides the skin as a possibl e place of origin , it has been shown 
that C lara cell-like cells and type II alveolar cells in the lung 
aJveolar endothe lium express an elafin precursor ofM, 14,000 [30]. 
T his find ing has been confirmed recently by the purification of a 
12-kD e lafin precursor fro m sputa of patients w ith chronic bron-
chitis as well as the cloning and sequencing of the gene for 
preproelafin derived fro m elaf:in mRNA extracted from C lara cell 
type carcinoma [31]. T he active e laf:i n molecule in the lung has 
been isolated fro m non-purulent sputum of a p atient w ith broncllia l 
carcinoma [32] and is identical to elaf:i n de rived from horny laye rs. 
A fragment of elafin with M , 2500 was recovered from purulen t 
sputum, indicatin g that it is an ac tive cleavage product of na tive 
e lafin starting afte r va line-9 [3 2]. Urinary e lafin as reported in this 
paper starts at g lycin e-7 , resul ting in the amino acid sequence 
GPVSTK ... as compared to the antiproteolytic fi·agmeut from 
lung e lafin , w hich starts with STK .. . [32], the latter being three 
residues shorter than urin ary elaf:i n . 
As a second so urce of urinary EIA, two bio logic active fragments 
of bikunin , the Kuni tz- type inhibito r subunit of inte r-a -inhibi to r 
found in plasm a, were iden tifi ed . 13ikunin was fo rm erly known as 
urinary tryps in inhibito r UTI, serum trypsin inhibito r STI, o r I-1130 
[1 9] and can be present in urine in va rio us m o lecul ar sizes ranging 
fi·01n its o•·ig inal reported M,. of67,000 [33] to an M,. be low LO,OOO 
[34], depending o n puri fi cation m ethods. As most purification 
m ethods in volve ac id treatment, it was tho ught that the weight 
m odificatio n was due to a pepsin-like enzym e presen t in urine tlwt 
cnn be activ ated in ac id condi t ions lower than pH 3.5 135]. Urinary 
bikunin is characte ri zed by its inhibi tory potential aga inst I-ILE [361, 
trypsin , chymot1y psin, and plasmin 133]. T he excretio n o f urin ary 
bikunin is in creased in patho logic states such as shock, acute 
infec tious diseases. advan ced tubercul osis, rh euma tic fever. renal 
disease, and cancer [35]. 
j: Wicdow 0. Young JA . Christaphers E: Molecular he rc rogcnccity of 
elastase sp<:c ific inhibitors derived fi·om psoriatic scales (abstr) . . ~t(h Denunt11l 
R es 2H4:2'! , IIJ92. 
566 STRBT ET AL 
Other antiproteases that may appear in urine arc a ,-proteinase 
inhibito r and antilcukoprotease. T he acid-instable a ,-proteinase 
inhibito r (M , 54,000) is the maj o r serine protease inhibitor of 
hum an plasma and was excl uded from the purifi cation procedure 
by acidifying the ut;nc sampl es to pH 1.0 for 30 m in [37]. Anti-
leukoprotcasc as a further possible HLE inhibitor is secreted by th e 
submucosal g lands of the upper and lower airways [38]. Antil eu-
koprotcase diffe rs fi·om c lafi n by the M,. of 12,000 and by its abili ty 
to inhibit ca thepsin G and bovin e t t-ypsin bu t not porcine pancreatic 
elastase [3 9]. Antile ukoprotease did not con tri bu te to the antipro-
teolytic activ ity found during the purifi cation process. N everthe-
less, the antip roteolytic activity in poo ls I and lll of th e first 
TSK-C M HPLC co uld contain antileukoproteasc, but these pools 
were eithe r lost on HPLC o r were too small fo r further purification . 
Alkemade cl a/ demonstrated inhibitory activities simila r to 
e lafin/SK.ALP in hu man urine [40]. It was shown that boiled uri.n c 
of psoriatic patients con tains a signifi cant amount of an ti- e lastase 
activi ty. Altho ugh an tileukop rotease and a 1-protcinase inhibi tor 
were excl uded by Westem blot techniqu e , fi·agments of urin ary 
bikunin, w hich have an HLE inhibitory activity, could be another 
source ofElA in urine. 
E lafin has recently been noted to be associated w ith th e m od u-
lation of cutaneous inAamm ation, e.g., in psoriasis [26). Ut;nary 
bikunin excretion is increased in bacteri al in fections and cancers 
[41]. Recent studies with intensive care patients have shown that a 
ri$C in elastase/ a ,-proteinase inhibitor complexes in p lasma appear 
to be highl y acc ura te in predicting the deve lopment of septicaemia 
[42]. Sensitive e lafi n and bikunin enzym e-linked immunosorbent 
assay wou ld provide an opportunity to evaluate the pred ic tive value 
of urinary protease inhibitors as markers for inA ammatory d iseases. 
Further investigations arc necessary to evaluate w hether e lafi n , an 
epitheli al-deri ved protease inhibitor, and bikunin , a plasma-derived 
protease in hibi to r, arc differentially regulated in inA amm atory 
diseases dependin g on the involvement of the epidermis. 
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